Products & Technology
VMT-𝛼-NET is entering a Phase 1 imaging study followed by a Phase 1 therapy study for neuroendocrine tumors at the University of Iowa.
Neuroendocrine tumors (NETs) are rare cancers that arise from cells of the endocrine and nervous systems. NETs often arise in the intestines (and can be referred to as carcinoids), but these tumors can also be found in the pancreas and other internal organs. There are several forms of NETs with pancreatic NETs accounting for about 7% of all pancreatic cancers and approximately 4,000 people will be diagnosed with pancreatic NETs in 2020. According to the American Cancer Society, the 5-year survival for patients experiencing distant pancreatic neuroendocrine tumors is approximately 25% and there are currently no curative treatments approved for NETs.
Viewpoint’s VMT-𝛼-NET radiopharmaceutical treatment and complementary imaging program was developed by CSO Michael K. Schultz PhD at the University of Iowa as part of the University’s Specialized Program of Research Excellence (SPORE) for NETs, a National Cancer Institute sponsored designation. The University of Iowa is the only NCI sponsored NET SPORE in the United States and is also a non-European based European Neuroendocrine Tumor Society Center of Excellence in NET patient care. Dr. Schultz developed VMT-𝛼-NET in collaboration with mentor Dr. M. Sue O’Dorisio as part of his Project Leader role on the NET SPORE team.
As with all Viewpoint therapeutics, VMT-𝛼-NET is designed to deliver powerful alpha particle radiation specifically to the cancerous NET, while minimizing risk to normal organs and tissues. In 2019, Dr. Schultz’s laboratory at the University of Iowa was awarded an R01 research grant from the National Cancer Institute to prepare for and conduct an image-guided alpha-particle therapy trial of VMT-𝛼-NET for NETs.
The first-in-human imaging trial is anticipated to commence in early 2021. Viewpoint has further been awarded over $4M in the form of Small Business Innovation Research grants from the National Cancer Institute to advance this cutting treatment to clinical development. Thus, the VMT-𝛼-NET receptor-targeted alpha-particle radiotherapy is positioned to advance a new transformative treatment paradigm for NET patients.
More information on pancreatic neuroendocrine tumors:
National Cancer Institute
(US National Institutes of Health) Awards
This work has been funded by the Small Business Innovation Research Grant program at the United States National Institutes of Health (National Cancer Institute) for awards of competitive grants and contracts that have contributed to the advancement of the company’s key programs VMT01; VMT-𝛼-NET; and VMT-𝛼-GEN.
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enabling the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.